Pipeline

At Sage we're advancing a leading brain health portfolio.

Compound
Partners
Indications
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Marketed
Depression Franchise
ZULRESSO
(brexanolone) CIV injection
Postpartum Depression
100
Zuranolone
(SAGE-217)
Major Depressive Disorder
79
Postpartum Depression*
79
Treatment Resistant
50
Generalized Anxiety Disorder
50
Bipolar Depression
40
NEUROLOGY FRANCHISE
SAGE-324
Essential Tremor
40
Epileptiform Disorders
29
Parkinson's Disease
29
SAGE-689
Acute GABA Hypofunction
19
NEUROPSYCHIATRY FRANCHISE
SAGE-718
Huntington's Disease Cognitive Dysfunction
40
Parkinson's Disease Cognitive Dysfunction
40
Alzheimer's Disease Mild Cognitive Impairment and Mild Dementia
40
ADDITIONAL CLINICAL PROGRAMS
SAGE-319
GABA Hypofunction
19
SAGE-421
NMDA Hypofunction
11

*Rolling submission of NDA in MDD initiated with FDA, which we expect to complete in 2H22

- - - indicates trials in the planning or evaluation stage

Please refer to the U.S. Prescription Information for brexanolone

Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result in the approval by a Health Authority.

We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use .
ACCEPT